How are leprosy reactions diagnosed and how do they differ from a dapsone hypersensitivity reaction?

Diagnosing Leprosy Reactions and Distinguishing from Dapsone Hypersensitivity

Leprosy reactions are diagnosed clinically based on the sudden onset of inflammation in existing leprosy lesions with or without systemic symptoms, while dapsone hypersensitivity syndrome presents 1-4 weeks after starting therapy with fever, exfoliative dermatitis, hepatic dysfunction, and methemoglobinemia—critically, dapsone reactions do NOT spare leprosy patches, whereas the anatopic phenomenon may cause DHS rashes to spare pre-existing leprosy lesions.

Diagnosing Leprosy Reactions

Type 1 Reaction (Reversal Reaction)

Type 1 reactions occur primarily in borderline leprosy patients and are characterized by:

• Acute inflammation of existing skin lesions with increased erythema, swelling, and pain in previously diagnosed leprosy patches 1, 2
• Neuritis presenting as acute nerve pain, tenderness, and new or worsening nerve function loss 1, 2
• Timing: Most commonly occurs during the first year of multidrug therapy (MDT), with 26.3% of borderline lepromatous patients experiencing reactions in year one, declining to 12.4% in year two 2
• Mechanism: Results from enhanced delayed hypersensitivity response to residual mycobacterial antigens as bacterial load decreases with treatment 1

Clinical pitfall: Type 1 reactions can occur at diagnosis (before treatment), during MDT, or even years after completing therapy—reactions have been documented up to 4 years post-treatment 2

Type 2 Reaction (Erythema Nodosum Leprosum - ENL)

ENL occurs mainly in lepromatous leprosy patients and presents with:

• Tender erythematous skin nodules that may become pustular or ulcerate 1, 3
• Systemic features: Fever, malaise, neuritis, orchitis, joint swelling, iritis, epistaxis 1
• Timing: Approximately 50% of lepromatous patients develop ENL in the first year of treatment, with 5.5% in year one and 2.8% in year two 2
• Histology: Vasculitis with intense polymorphonuclear infiltrate 1
• Mechanism: Immune complex-mediated (Type 3 hypersensitivity) 1

Rare presentation: Bullous ENL can occur and must be differentiated from drug reactions and other blistering diseases 3

Diagnosing Dapsone Hypersensitivity Syndrome (DHS)

DHS is a severe, potentially fatal drug reaction with distinct clinical features:

Timing and Clinical Presentation

• Onset: 1-4 weeks (typically 6-8 weeks) after starting dapsone therapy 4, 1, 5
• Classic triad: Fever, exfoliative dermatitis, and hepatic dysfunction 4, 1
• Additional features: Methemoglobinemia, lymphadenopathy, atypical lymphocytosis, eosinophilia 1, 5

Laboratory Findings

• Leukocytosis with eosinophilia 5
• Atypical lymphocytosis 5
• Elevated liver enzymes (hepatic and canalicular) 5, 6
• Methemoglobinemia 1

Key Diagnostic Feature: The Anatopic Phenomenon

A pathognomonic finding that distinguishes DHS from leprosy reactions:

• DHS rash characteristically SPARES pre-existing hypopigmented leprosy patches 6, 7
• This "anatopic response" occurs because the Th17 inflammatory response in leprosy lesions, coupled with subepidermal collagen bands, prevents DHS rash manifestation at those sites 6, 7
• Immunohistology of DHS rash: Strong Th1 cytokine expression (IL1β, TNFα, IFNγ, iNOS) with limited IL17 expression 6
• Immunohistology of spared leprosy patches: High Th1 AND strong Th17/TGFβ expression 6

Critical Distinctions Between Leprosy Reactions and DHS

Leprosy Reactions (Type 1 and ENL):

• Affect existing leprosy lesions with increased inflammation in previously diagnosed patches 1, 2
• Do NOT require discontinuation of dapsone 1
• Treatment: Continue anti-leprosy therapy; add corticosteroids for severe reactions or neuritis 1, 2
• Recurrence pattern: 71% may experience recrudescence during treatment course 8

Dapsone Hypersensitivity Syndrome:

• New diffuse rash that SPARES leprosy patches (anatopic phenomenon) 6, 7
• Requires immediate discontinuation of dapsone 1
• Systemic involvement: Hepatic dysfunction, lymphadenopathy, hematologic abnormalities 1, 5
• Timing: Fixed window of 1-4 weeks post-initiation 1, 5
• Recrudescence: 71% experience symptom reflare ~20 days after dapsone cessation, possibly related to herpesvirus reactivation (39% show HHV-5/6 presence) 8

Risk Factors for DHS

Predictive factors for developing DHS in leprosy patients:

• Female sex (OR 3.61) 9
• Multibacillary classification (OR 2.5) 9
• Higher education level (OR 1.97) 9

Management Algorithm

When a patient on dapsone develops new skin manifestations:

1. Assess timing: <4 weeks from dapsone initiation suggests DHS; later onset or pre-existing lesion inflammation suggests leprosy reaction 1, 2, 5

2. Examine lesion distribution:

   • Inflammation of pre-existing leprosy patches = leprosy reaction 1, 2
   • New diffuse rash sparing leprosy patches = DHS 6, 7

3. Check for systemic features:

   • Hepatic dysfunction + lymphadenopathy + eosinophilia = DHS 1, 5
   • Isolated neuritis or nodules = leprosy reaction 1

4. Laboratory evaluation:

   • Complete blood count with differential (eosinophilia, atypical lymphocytes) 5
   • Liver function tests 5
   • Methemoglobin level if DHS suspected 1

5. Treatment decision:

   • If DHS: Immediately discontinue dapsone, initiate corticosteroids (IV dexamethasone or high-dose oral prednisolone) 1, 5, 7
   • If leprosy reaction: Continue dapsone, add prednisolone for severe cases or neuritis 1, 2

Critical warning: DHS is associated with agranulocytosis, aplastic anemia, and death—any suspicion warrants immediate dapsone discontinuation 1